Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1990 Mar;61(3):434–435. doi: 10.1038/bjc.1990.95

Increased levels of soluble interleukin-2 receptors in serum of patients with lung cancer.

P Marino 1, M Cugno 1, A Preatoni 1, P Cori 1, A Rosti 1, L Frontini 1, M Cicardi 1
PMCID: PMC1971291  PMID: 2158340

Full text

PDF
434

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Colvin R. B., Fuller T. C., MacKeen L., Kung P. C., Ip S. H., Cosimi A. B. Plasma interleukin 2 receptor levels in renal allograft recipients. Clin Immunol Immunopathol. 1987 May;43(2):273–276. doi: 10.1016/0090-1229(87)90135-8. [DOI] [PubMed] [Google Scholar]
  2. Kloster B. E., John P. A., Miller L. E., Rubin L. A., Nelson D. L., Blair D. C., Tomar R. H. Soluble interleukin 2 receptors are elevated in patients with AIDS or at risk of developing AIDS. Clin Immunol Immunopathol. 1987 Dec;45(3):440–446. doi: 10.1016/0090-1229(87)90095-x. [DOI] [PubMed] [Google Scholar]
  3. Malkovský M., Sondel P. M., Strober W., Dalgleish A. G. The interleukins in acquired disease. Clin Exp Immunol. 1988 Nov;74(2):151–161. [PMC free article] [PubMed] [Google Scholar]
  4. O'Garra A. Interleukins and the immune system 1. Lancet. 1989 Apr 29;1(8644):943–947. [PubMed] [Google Scholar]
  5. Oliver R. T. The clinical potential of interleukin-2. Br J Cancer. 1988 Oct;58(4):405–409. doi: 10.1038/bjc.1988.230. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Pizzolo G., Chilosi M., Semenzato G. The soluble interleukin-2 receptor in haematological disorders. Br J Haematol. 1987 Dec;67(4):377–380. doi: 10.1111/j.1365-2141.1987.tb06156.x. [DOI] [PubMed] [Google Scholar]
  7. Pizzolo G., Chilosi M., Vinante F., Dazzi F., Lestani M., Perona G., Benedetti F., Todeschini G., Vincenzi C., Trentin L. Soluble interleukin-2 receptors in the serum of patients with Hodgkin's disease. Br J Cancer. 1987 Apr;55(4):427–428. doi: 10.1038/bjc.1987.83. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Rosenberg S. A., Lotze M. T., Muul L. M., Chang A. E., Avis F. P., Leitman S., Linehan W. M., Robertson C. N., Lee R. E., Rubin J. T. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med. 1987 Apr 9;316(15):889–897. doi: 10.1056/NEJM198704093161501. [DOI] [PubMed] [Google Scholar]
  9. Rovelli F., Lissoni P., Crispino S., Barni S., Fumagalli G., Paolorossi F., Tancini G. Increased level of soluble interleukin-2 receptor in advanced solid tumors: a preliminary study. Tumori. 1988 Dec 31;74(6):633–637. doi: 10.1177/030089168807400603. [DOI] [PubMed] [Google Scholar]
  10. Uchiyama T., Broder S., Waldmann T. A. A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells. I. Production of anti-Tac monoclonal antibody and distribution of Tac (+) cells. J Immunol. 1981 Apr;126(4):1393–1397. [PubMed] [Google Scholar]
  11. Wang H. M., Smith K. A. The interleukin 2 receptor. Functional consequences of its bimolecular structure. J Exp Med. 1987 Oct 1;166(4):1055–1069. doi: 10.1084/jem.166.4.1055. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. West W. H., Tauer K. W., Yannelli J. R., Marshall G. D., Orr D. W., Thurman G. B., Oldham R. K. Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med. 1987 Apr 9;316(15):898–905. doi: 10.1056/NEJM198704093161502. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES